Concurrently, PRP suppresses gluconeogenesis via PEPCK1 downregulation (110) and mitigates insulin resistance through Nrf2/HO-1-mediated antioxidant pathways (20, 50, 52). Here, NFE2L2 is linked to Insulin resistance.